SCHEMBL19679999

SCHEMBL19679999

CNC(Cc1ccc(C(C)C)cc1)C(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.50
ESR1 P03372 2/20 0.45
EPHX1 P07099 1/20 0.45
ESR2 Q92731 1/20 0.45
CHRM1 P11229 1/20 0.42
PDE4A P27815 1/20 0.42
PTGS1 P23219 3/20 0.42
PTGS2 P35354 3/20 0.42
CXCR1 P25024 3/20 0.42
CXCR2 P25025 3/20 0.42
LMNA P02545 2/20 0.42
CYP2C9 P11712 2/20 0.42
AKR1C3 P42330 2/20 0.42
ALOX5 P09917 2/20 0.42
ALB P02768 1/20 0.42
RARB P10826 1/20 0.42
ADRB3 P13945 1/20 0.42
NFKB1 P19838 1/20 0.42
HTR2A P28223 1/20 0.42
NR1I3 Q14994 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14898395 1.00 ACACB (0.50) ACACBESR1EPHX1ESR2CHRM1
SCHEMBL7999700 0.84 CA2 (0.43) ESR1EPHX1ESR2TSHRRAB9A
SCHEMBL15315079 0.84 CA2 (0.43) ESR1EPHX1ESR2TSHRRAB9A
SCHEMBL13323474 0.84 ACACB (0.48) ACACBCYP2C9MEN1KMT2APPARG
SCHEMBL12188588 0.84 ACACB (0.48) ACACBCYP2C9MEN1KMT2APPARG
SCHEMBL14950914 0.84 ACACB (0.48) ACACBCYP2C9MEN1KMT2APPARG
SCHEMBL8272777 0.82 RXRA (0.54) ACACBPTGS2ADRB3PPARGALDH1A1
SCHEMBL12568338 0.82 NPC1 (0.42) ACACBNFKB1RAB9AMEN1KMT2A
SCHEMBL9886030 0.82 ACACB (0.46) ACACBESR1ESR2MEN1KMT2A
SCHEMBL12668874 0.82 ACACB (0.46) ACACBESR1ESR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349638-A1 COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2017-12-07 US disclosed
US-20170349638-A1 COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349638-A1 COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES TP53, TP53BP1, VHL ACACB 3730/4885ESR1 442/4885EPHX1 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.